Amarin Corp Plc (AMRN)

[Tatsumaki]

Mochida filed their self emulsifying patent in 2013, it was granted in 2015. Well before the agreement to collaborate and develop anything with Amarin in 2018. It's Mochida's IP that Amarin bought exclusive distribution rights to. Amarin doesnt own that particular IP at all and didnt help develop it. They bought the rights to sell it. So I still say its doubtful acquirer can just buy Amarin and get access to Mochida's IP without Mochida having a say in the matter or even a way to cancel the agreement entirely. Perhaps you could argue co ownership of anything developed by both parties after the signed agreement, but self emulsifying IP predates that.

And as far as your statement "commercialize it everywhere, but in Japan as the agreement spells out", then why is Mochida and Sumitomo running P3 trials in China with it and not Amarin?